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Background: Extracellular gelsolin (GSN) and GC-globulin/Vitamin D-binding protein (DBP) appear to play an
important role in clearing the actin from extracellular fluids and in modulating cellular responses to anionic
bioactive lipids. In this study we hypothesized that cellular actin release and/or increase in bioactive lipids
associated with multiple sclerosis (MS) development will translate into alteration of the actin scavenger system
protein concentrations in blood and cerebrospinal fluid (CSF) of patients with MS.
Methods: We measured GSN and DBP concentrations in blood and CSF obtained from patients diagnosed with
MS (n = 56) in comparison to a control group (n = 20) that includes patients diagnosed with conditions such as
idiopathic cephalgia (n = 11), idiopathic (Bell’s) facial nerve palsy (n = 7) and ischialgia due to discopathy (n = 2).
GSN and DBP levels were measured by Western blot and ELISA, respectively.
Results: We found that the GSN concentration in the blood of the MS group (115 ± 78 μg/ml) was significantly
lower (p < 0.001) compared to the control group (244 ± 96 μg/ml). In contrast, there was no statistically significant
difference between blood DBP concentrations in patients with MS (310 ± 68 μg/ml) and the control group (314 ±
82 μg/ml). GSN and DBP concentrations in CSF also did not significantly differ between those two groups.
Conclusions: The decrease of GSN concentration in blood and CSF of MS subjects suggests that this protein may
be involved in chronic inflammation associated with neurodegeneration. Additionally, the results presented here
suggest the possible utility of GSN evaluation for diagnostic purposes. Reversing plasma GSN deficiency might
represent a new strategy in MS treatment.
Background
Actin binding is a common characteristic of both gelso-
lin and GC-globulin, also known as vitamin D binding
protein. Gelsolin was first described as a ~90 kDa cyto-
plasmic actin-binding protein involved in the remodel-
ing of cellular actin filaments associated with cell shape
changes and movement [1]. Further studies revealed a
secreted gelsolin isoform in the blood plasma [2,3]. As
plasma gelsolin has the ability to bind actin, blood gel-
solin depletion was observed in diverse states of inflam-
mation associated with tissue injury and actin release:
adult respiratory distress syndrome, sepsis, myocardial
infarction, hepatitis, myonecrosis and rheumatoid arthri-
tis [4-7]. In trauma patients, lower plasma gelsolin levels
were associated with a poor prognosis [8]. Poor prog-
nosis associated with lower plasma gelsolin levels was
also shown in critically ill surgical patients [9] and in
patients subjected to hemodialysis [10].
DBP acts as a carrier protein for vitamin D, but it can
also be converted into a macrophage activating factor
[11]. One of DBP’s most important functions is to act as
part of an extracellular actin scavenger system (EASS)
[12,13]. This system is designed to remove actin from
the blood plasma where it can form long filaments that
can trigger intravascular coagulation and toxicity to
endothelial cells [14,15]. In the actin scavenging system,
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meric G-actin in order to prevent polymerization. This
process allows actin to be cleared by the liver, but at the
same time it consumes DBP and gelsolin [16,17]. Similar
to gelsolin depletion, low DBP levels (both the total level
and the actin-free level, which is an index of residual
actin-scavenging capacity), was proposed to serve as a
prognostic marker in situations of organ damage such
as acute liver failure, and multiple trauma [18]. Other
conditions such as septic shock may also be associated
with reduced DBP levels and complex formation with
actin [19]. In addition to actin, gelsolin and DBP bind
important bioactive lipids. Gelsolin was shown to prefer-
entially bind lysophosphatidic acid, platelet-activating
factor, endotoxin, and lipoteichoic acid [20-22]. DBP
specifically interacts with arachidonic acid, a precursor
of prostaglandins [23]. Gelsolin’s interaction with bioac-
tive lipids can alter its ability to bind actin [24].
Multiple sclerosis (MS) is an immune-mediated
demyelinating disorder of the human central nervous
system. There is increasing evidence that axonal degen-
eration plays an important role in the pathogenesis of
this disease. Some studies show that axonal cytoskeletal
proteins such as actin, tubulin or the neurofilament
light subunit (NFL) can be detected in CSF and blood
from patients with neurodegenerative conditions and
that the presence of these proteins might serve as useful
confirmation of neurodegeneration or MS progression
[25,26]. Analysis of gelsolin and DBP concentrations
suggests the consideration of EASS protein analysis for
diagnostic purposes. Additionally, hypogelsolinemia




Human blood and CSF specimen collection was per-
formed in the Department of Neurology at the Medical
University of Białystok in accordance with a protocol
approved by the Medical University of Białystok Ethics
Committee for Research on Humans and Animals, and
written consent was obtained from all subjects. All indivi-
duals were already undergoing lumbar puncture for diag-
nostic purposes. Shortly after collection, samples of
cerebrospinal fluid and blood were centrifuged (2000 × g,
20 min), and the supernatants of CSF and blood plasma
were subjected to total protein analysis and frozen. The
degree of neurological impairment in patients diagnosed
with MS, from whom CSF was obtained, was evaluated
using the Expanded Disability Status Scale (EDSS). All
evaluations rated on average 1.5 ± 0.6, which indicates
the early stages of MS. All MS patients suffered from the
relapsing-remitting form of the disease and were
not being treated with any disease-modifying drugs
(beta-interferon, glatiramer acetate, natalizumab) or glu-
cocorticosteroids at the time of hospital admission.
Clinically, all MS patients included in the study repre-
sent category 1 or 2 according to the McDonald criteria
[27]. All have a history of at least two neurological
attacks (indicative of dissemination in time) and their
single MRI shows T2-hyperdense lesions in different
parts of the brain, but not all patients meet the Bar-
khof’s MRI criteria of MS diagnosis [28]. Therefore, the
lumbar puncture was performed to obtain a definitive
diagnosis of MS. All CSF samples were clear, with the
average number of lymphocytes equal to 4.1, and aver-
age Cl- and total protein concentrations of 132 ±
2.9 mEq/l and 381 μg/ml, respectively (Table 1). More
importantly, oligoclonal bands type 2 or 3 were present
in all CSF samples obtained from MS subjects, and
QALB values indicate lack of blood/CSF barrier
dysfunction in all subjects included in this study. We
collected samples from 56 patients diagnosed with MS.
H o w e v e r ,d u et os o m es m a l lC S Fs p e c i m e n s ,w ew e r e
able to perform both gelsolin and DBP analysis in only
24 samples.
Immunoblotting of gelsolin in blood and CSF
Gelsolin concentration was assessed as previously
described [29]. Briefly, after thawing, gel sample buffer
was added to the plasma and CSF samples, which were
then boiled and subjected to electrophoresis on 10%
sodium dodecyl sulfate (SDS) - polyacrylamide minigels.
Recombinant human plasma gelsolin was loaded as a
positive control in each gel in a concentration range
comparable to the gelsolin concentration in the samples
(7.5 - 30 ng). After electrophoresis, proteins were trans-
ferred to PVDF membranes (Amersham, Biosciences
Little Chalfont, UK), which were blocked by incubation
in 5% (w/v) non-fat dry milk dissolved in TBS-T (150
mM NaCl, 50 mM TRIS, 0.05% Tween 20, pH = 7.4).
Following transfer, proteins were probed with a mono-
clonal anti-human gelsolin antibody (G4896, Sigma,
St. Louis, MO, USA) used at a 1:10,000 dilution in TBS-
T. HRP-conjugated secondary antibodies were used at a
1:20,000 dilution in TBS-T. Immunoblots were devel-
oped with the Fuji Film LAS-300 system using an ECL
Plus HRP-targeted chemiluminescent substrate (Amer-
sham, Biosciences Little Chalfont, UK). The integrated
intensity of each band on the Western Blot, minus the
background signal was quantified with densitometrical
analysis (Image Gauge - version 4.22 software; Fuji
Photo Film Co, USA). All analyses were performed
blind to clinical data.
Determination of CG-globulin concentration
DBP was measured using a sandwich enzyme-linked
immunosorbent assay (ELISA, BioPorto Diagnostics DK-
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turer’s instructions.
Identification of F-actin in CSF samples obtained from
MS patients
F-actin presence in cerebrospinal fluid was evaluated
using a technique previously used to detect F-actin in
sera collected from patients with adult respiratory dis-
tress syndrome [15]. Briefly, CSF samples were subjected
to centrifugation (13,500 × g, 4°C, for 20 min.), then
20 μl (1:200 dilution) of rhodamine (TRITC) phalloidin
(Sigma, St Louis MO, USA) was added to the pellet. Sam-
ples were viewed in a Leica microscope (Bannockbum,
IL, USA) using a 10× objective. Images were captured
with a Cool SNAP(HQ) camera (Trenton, NJ, USA).
Statistical analysis
Data are reported as mean ± SD from 20-40 specimens.
Differences between means were evaluated using the
unpaired Student’s t-test, with p < 0.05 being taken as
the level of significance. Additionally, values of gelsolin
and DBP concentration in blood and CSF were com-
pared using Pearson’s correlation test.
Results
Gelsolin and vitamin D binding protein concentration
in blood
Using quantitative western blot analysis we detected
significantly lower (p < 0.001) gelsolin concentration in
the blood of MS subjects (Figure 1) compared to the
gelsolin concentration in our control group (115 ± 78
versus 244 ± 96 μg/ml). There was no significant differ-
ence between DBP levels in blood of MS patients and
the control group (310 ± 68 μg/ml versus 314 ± 82),
determined using ELISA. In the MS group, circulating
gelsolin and DBP levels were similar in both males and
females and were also not dependent on patient age. As
all patients included in MS group were suffering from
the relapsing-remitting form of the disease at early
stages (Table 1), it may be concluded that depletion of
plasma gelsolin represents an early event during MS
development. Average gelsolin concentration in blood of
MS patients was significantly lower (p < 0.001)
compared to blood concentrations of vitamin D binding
protein.
Gelsolin and DBP concentration in cerebrospinal fluid
Our previous study showed that GSN present in CSF of
MS patients consists predominantly of its plasma
Table 1 Clinical and laboratory characteristics of the patient groups.
CSF
Clinical group Total number (females) Age (years) EDSS Q(Alb) Total protein (μg/ml) Lymphocytes
MS* 56 (30) 37.5 ± 10.5 1.5 ± 0.6 6.5 ± 1.1 381 ± 132 4.1 ± 2.3
Control:
idiopathic cephalgia 11(9) 45.3 ± 25.3 N/A 6.9 ± 1.4 401 ± 165 3.1 ± 2.1
idiopathic (Bell’s) facial nerve palsy 7(4) 52.2 ± 18.6 N/A 7.2 ± 0.8 360 ± 182 5.3 ± 2.2
ischialgia due to discopathy 2(0) 45.1 ± 26.2 N/A 6.8 ± 1.8 391 ± 192 4.2 ± 1.1
QAlb - albumin CSF/serum quotient. * oligoclonal IgG bands (type 2 or 3) were present in CSF of all subjects included in this group
Figure 1 Gelsolin (panel A) and Vitamin D binding protein
(panel B) concentrations in blood collected from control
patients (left) and subjects diagnosed with multiple sclerosis
(right). Horizontal bars depict means. *p < 0.001 compared to
gelsolin concentration in control group.
Kułakowska et al. BMC Neurology 2010, 10:107
http://www.biomedcentral.com/1471-2377/10/107
Page 3 of 8isoform, and using immunoblotting assays, we have not
observed any cleavage products of pGSN in CSF [30].
Here we report that average gelsolin concentrations in
CSF collected from patients diagnosed with MS was
lower (2.9 ± 1.8 versus 4.1 ± 1.7 μg/ml) and the average
DPB level was higher (1.6 ± 0.9 versus 1.4 ± 0.8 μg/ml)
compared to the control group (Figure 2). The average
gelsolin concentration in the CSF of MS patients was sig-
nificantly higher (p < 0.001) than the concentration of vita-
min D binding protein, showing that these plasma
proteins do not simply partition passively into the CSF.
Additionally, an analysis using Pearson’s test indicated a
weak correlation between gelsolin levels in CSF and its
level in blood. A similar comparison for DBP also indicates
a correlation between DBP concentrations in CSF and
blood. However this correlation is weaker compared to
that found for gelsolin levels in blood and CSF of MS sub-
jects. The direction of gelsolin and DBP concentration
changes in CSF (average values calculated based on 40 MS
patients included in each group) suggests the possibility
that depletion of CSF gelsolin levels might be compen-
sated for by an increase in DBP concentration (Figure 2),
but this statement is not supported by r (r = 0.4242) and p
(p < 0.005) values calculated using Pearson’s correlation
test (it included 24 subjects in which GSN and DBP was
analyzed in the same samples) indicating occurrence of
positive correlation between those values in the same
patients, potentially meaning that in subjects with higher
CSF gelsolin concentration, higher DBP concentration is
more likely to be observed (Figure 3).
Presence of F-actin in CSF of MS subjects
According to previous reports, F-actin is present in CSF
of patients suffering from MS. However, we have not
seen detectable amounts of actin in specimens of CSF
collected from MS patients or some of our control
group patients in Western blot analysis (data not
shown). However, F-actin was detected in the pellets
generated after centrifugation of ~250 μl of CSF samples
followed by addition of rhodamine-phalloidin and
microscopic observation (Figure 4).
Discussion
This study confirms our previous report of a decrease of
gelsolin concentration in the blood and CSF of a small
group of MS patients (n = 4) [30]. For the current
study, specimens were collected from 56 MS patients
suffering from the relapsing - remitting form of the dis-
ease at early stages. Specimens were then subjected to
analysis of the extracellular actin scavenger system pro-
teins GSN and DBP. The results reveal significantly
lower gelsolin concentration in blood of the MS group
compared to the control group. However, lowered gelso-
lin concentration in CSF samples did not reach statisti-
cal significance when compared to its concentration in
the control group. We have not observed any significant
differences in DBP concentration in blood or CSF of
MS subjects in comparison to the control, but the aver-
age DPB concentration in CSF from MS patients was
marginally higher compared to the concentration in the
control group.
The cause of observed EASS protein concentration
changes in MS samples is unclear, but based on existing
reports indicating higher levels of actin in CSF of MS
patients [25], the presence of extravascular fibrinogen in
MS lesions [31,32], dysfunction of the blood-brain bar-
rier (BBB) associated with MS development, and the fact
that the CNS itself becomes an immunological compart-
ment with increasing cytokine production during the
course of the disease [33], several possibilities can be
Figure 2 Gelsolin (panel A) and Vitamin D binding protein
(panel B) levels in cerebrospinal fluid collected from control
patients (left) and subjects diagnosed with multiple sclerosis
(right). Horizontal bars depict means.
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degeneration results in the release of actin and other
cytoskeletal proteins within the intrathecal compart-
ment, which may potentially mobilize blood EASS pro-
teins to the CNS. Such mobilization would account for
the decrease of gelsolin in blood, assuming that normal
blood levels cannot be maintained by increasing produc-
tion, which in the case of gelsolin occurs in muscle and
neurons, but not liver. At the same time, higher demand
for vitamin D binding protein will be filled more effec-
tively by increased liver production of this acute phase
reactant, which would explain the lack of significant
changes in the DBP blood concentration. The
identification of actin in the sediments of CSF obtained
after centrifugation represents strong evidence to sup-
port this possibility. At the same time, these results are
in agreement with the sequestration hypothesis that was
proposed as a mechanism of actin-mediated gelsolin
depletion [34]. The QAlb values indicate lack of CSF-
barrier dysfunction in MS subjects included in our
study, and it is very likely that the depletion of GSN
a n dD B Pf r o mC S Ft h a to c c u r sa st h e s ep r o t e i n sb i n d
actin cannot be compensated for by an increased pro-
duction or transport of gelsolin. Interestingly, in one
recent study, up-regulation of gelsolin and DBP in CSF
was reported for a pediatric MS group (n = 12) [35]
Figure 3 Correlation between the blood and cerebrospinal fluid levels of gelsolin (panel A), the blood and cerebrospinal fluid levels
of Vitamin D binding protein (panel B), blood gelsolin and blood DBP (panel C) and cerebrospinal fluid levels of DBP and gelsolin
(panel D) in patients diagnosed with multiple sclerosis (MS). Panels A/B and C/D include concentration values from 40 and 24 patients,
respectively.
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brospinal fluid GSN and DBP concentrations may
indeed increase in some stage of the disease. On the
other hand, we observed a decrease of GSN in blood
and CSF, which agrees with a study showing that a
decrease of blood gelsolin level is inversely related to
the intensity of systemic inflammation in patients with
rheumatoid arthritis (RA) [7]. RA is a chronic inflamma-
tory condition that shares similar pathophysiological
processes with MS [36]. In addition, RA patients have
significantly lower intra-articular plasma gelsolin levels
in addition to the presence of actin-gelsolin complexes.
On the other hand, in recent studies overexpression of
gelsolin restored the impaired mitochondrial activity
associated with CNS degeneration in the course of Alz-
heimer’s disease (AD). Therefore, cytoplasmic gelsolin
might act as a modulator of brain Abeta levels and its
neurotoxic effects during AD development and may
decrease neurodegeneration in AD [37].
Evaluation of MS biomarkers related to disease
mechanisms, disease activity and progression, or thera-
peutic response is of great interest [38]. Our data give
only a limited view of MS development and progression,
and may be see as a preliminary result, so further long-
term studies are required to evaluate the prognostic
value of EASS protein level analysis as a biochemical
marker for predicting and monitoring neurological
decline in the course of MS. It is possible that EASS pro-
tein evaluation, especially gelsolin, in combination with
other biomarker candidates such as neurofilament light
chains, tau protein, actin, or tubulin, will increase diag-
nostic accuracy and better assessment of MS progression.
Conclusion
The decrease of GSN concentration in blood and CSF of
MS subjects indicates the involvement of this protein in
the process of neurodegenerative disease development.
Additionally, the results presented here suggest the pos-
sible utility of GSN evaluation for diagnostic purposes.
Hypogelsolinemia represents a target for MS therapeutic
intervention
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